The plaintiff alleges that Novo Nordisk knew or should have known that Ozempic carried a risk of NAION and failed to adequately disclose that risk to prescribing physicians or patients
It is characterized by high blood glucose levels
[7] In a Bayesian network meta-analysis of 48 randomized trials and nearly 28,000 participants, the dominant gastrointestinal events were nausea (about 21.5%), diarrhea (10.6%), vomiting (9.1%), and constipation (7.9%), with semaglutide carrying one of the highest constipation risks
Animal studies suggested that the spiro-derivatives reduced toxicity may be attributed to lower cardiotoxicity, as evidenced by less QRS widening in isolated guinea pig hearts
As replacements that 'mimic' or 'boost' GLP-1 on their own, the effect is far weaker than the medication and the big claims are mostly marketing